Management of Isoniazid-Induced Hepatitis
Stop isoniazid immediately if AST exceeds 3 times the upper limit of normal with symptoms OR exceeds 5 times the upper limit of normal without symptoms 1, 2.
Immediate Actions When Hepatitis is Suspected
When drug-induced hepatitis occurs, you must:
- Discontinue all hepatotoxic TB medications immediately (isoniazid, rifampin, and pyrazinamide) 1
- Obtain serologic testing for hepatitis A, B, and C if not done at baseline 1
- Question the patient carefully about other hepatotoxin exposures, especially alcohol 1
- Initiate alternative TB treatment with 2 or more non-hepatotoxic agents such as ethambutol, streptomycin, amikacin/kanamycin, capreomycin, or a fluoroquinolone (levofloxacin, moxifloxacin, or gatifloxacin) until the cause is identified 1
Sequential Reintroduction Protocol
Once hepatitis resolves (AST decreases to less than 2 times the upper limit of normal AND symptoms significantly improve), restart first-line medications sequentially 1:
- Reintroduce drugs one at a time in very small, gradually increasing doses 2
- Withdraw immediately if any indication of recurrent liver involvement 2
- Close monitoring with repeat AST, bilirubin measurements, and symptom review is essential 1
Critical caveat: If hepatitis was attributed to isoniazid, consider alternative drug regimens permanently. Continued use after symptoms appear causes more severe liver damage 2. The FDA label explicitly warns that restarting should only occur after complete resolution and with extreme caution 2.
Monitoring Requirements
The FDA mandates specific monitoring based on risk factors 2:
- For patients ≥35 years: Measure AST and ALT before starting therapy and periodically throughout treatment 2
- Monthly clinical interviews for ALL patients to assess symptoms 2
- More frequent monitoring for high-risk groups: daily alcohol users, chronic liver disease, injection drug users, women (particularly Black and Hispanic women, especially postpartum) 2
Warning Signs Requiring Immediate Discontinuation
Instruct patients to immediately report 2:
- Unexplained anorexia, nausea, vomiting
- Dark urine or jaundice
- Persistent paresthesias of hands and feet
- Persistent fatigue, weakness, or fever >3 days
- Abdominal tenderness, especially right upper quadrant discomfort
The median time to symptom onset is 16 weeks, with most cases occurring in the first 3 months 3, 4. However, late-onset hepatitis (>1 month) carries a worse prognosis and may be related to pyrazinamide when used in combination 3.
Risk Stratification
Age-related hepatitis rates per 1,000 patients 2:
- <20 years: <1 per 1,000
- 20-34 years: 3 per 1,000
- 35-49 years: 12 per 1,000
- 50-64 years: 23 per 1,000
65 years: 8 per 1,000
Important: When properly monitored according to current guidelines, the fatal hepatitis rate is negligible (0.001% or 2 per 202,497 patients) 5. This is substantially lower than older estimates and supports the safety of isoniazid when appropriate monitoring is implemented.
Special Populations
HCV-coinfected patients: Can receive isoniazid with appropriate monitoring. Transaminase elevations occur in 22% but are associated with concurrent alcohol use rather than HCV status itself. Drug discontinuation rates (8%) are within acceptable ranges 6.
Patients with baseline liver abnormalities: Should NOT receive pyrazinamide 3. Consider alternative regimens entirely or use isoniazid alone with intensive monitoring.